Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water...

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Development

Background:

• Developing novel chemotherapy strategies for malignancies is crucial.
• Paclitaxel prodrugs offer a potential avenue for improved cancer treatment.
• Targeting specific active sites, like the C7 hydroxyl group, can modulate drug properties.

Purpose of the Study:

• To synthesize and evaluate a paclitaxel prodrug with a pH-dependent, slow-release mechanism.
• To assess the prodrug's cytotoxicity, solubility, and in vivo antitumor efficacy.
• To determine if prodrug modification enhances therapeutic potential compared to paclitaxel.

Main Methods:

• Synthesis of a paclitaxel prodrug by blocking the C7 hydroxyl group with a dihydroxypropyl side chain.
• In vitro cytotoxicity testing against human tumor cell lines.
• In vitro cell cycle analysis to assess G2M arrest.
• Evaluation of water solubility and pH-dependent hydrolysis.
• In vivo studies in mice to determine maximum tolerated dose (MTD) and antitumor activity.

Main Results:

• The paclitaxel prodrug exhibited similar in vitro cytotoxicity to paclitaxel.
• The prodrug demonstrated over 50-fold increased water solubility compared to paclitaxel.
• pH-dependent hydrolysis effectively converted the prodrug back to paclitaxel.
• The prodrug achieved a 3-fold higher MTD in mice.
• Markedly improved antitumor activity was observed in mice treated with the prodrug.

Conclusions:

• The developed paclitaxel prodrug is effectively activated by pH-dependent hydrolysis.
• This prodrug offers significantly enhanced water solubility and superior in vivo antitumor efficacy over paclitaxel.
• This hydrolytically activated prodrug represents a promising strategy for improved malignancy treatment.